Health ❯ Healthcare ❯ Patient Care

Treatment Protocols

Neoadjuvant Therapy Combination Therapy Infusion Therapy Adjuvant Therapy Combination Therapies First-line Therapy Personalized Medicine Emergency Care Intravenous Therapy Controlled Access Programs

French Watchdog Finds Severe Rights Breaches and Unusual Death Toll at Melun Psychiatric Unit

The Health Ministry must answer the report within four weeks.

FDA Approves Nivolumab Plus AVD as First-Line Therapy for Advanced Hodgkin Lymphoma

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Trial Finds Some Early Breast Cancer Patients Can Skip Sentinel Node Biopsy Without Harming 5-Year Control

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Immunotherapy Before 3 p.m. Linked to Longer Survival in Small Cell Lung Cancer

Swedish Study Ties Lower Ipilimumab Dose to Longer Survival and Less Toxicity in Advanced Melanoma

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

EndRAD Phase 2 Finds Non-TBI Conditioning Matches Outcomes in MRD-Negative Young B-ALL

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

Vaccimel, Argentina's Melanoma Immunotherapy, Enters Commercial Use

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

NHS Trials 15-Minute Blood Test in Children’s A&Es to Speed Sepsis and Meningitis Care

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC